Urinary tract infection treatment in men
Pro Research Analysisby 
Searched over 200M research papers
Antibiotic Choices for Urinary Tract Infection Treatment in Men
The most commonly used antibiotics for treating urinary tract infections (UTIs) in men are fluoroquinolones (such as ciprofloxacin), trimethoprim-sulfamethoxazole, nitrofurantoin, and pivmecillinam. Fluoroquinolones are often the first choice, especially for febrile or complicated cases, but concerns about resistance and side effects have led to increased interest in alternatives like nitrofurantoin and pivmecillinam, particularly for lower UTIs. These alternatives are effective against Escherichia coli and have a lower impact on gut microbiota, making them suitable for empirical treatment of lower UTIs in men 258.
Treatment Duration: Short vs. Long Courses
Afebrile Men with UTI
For afebrile men with uncomplicated UTIs, evidence shows that a 7-day course of antibiotics is as effective as a 14-day course for symptom resolution and recurrence prevention. Shorter treatment does not increase the risk of recurrence or adverse events, and helps reduce the risk of antibiotic resistance and side effects 146.
Febrile Men with UTI
In contrast, for men with febrile UTIs, a 14-day course of antibiotics is more effective than a 7-day course. Shorter treatment in these cases leads to lower rates of treatment success, so a full 14-day regimen is recommended for febrile infections 35.
Special Considerations: Prostatic Involvement
Some men with febrile UTIs may have subclinical prostatic involvement, which can be detected by elevated prostate-specific antigen (PSA) levels. For those without PSA elevation, a 2-week antibiotic regimen is generally sufficient, with similar cure and recurrence rates compared to longer courses .
Recurrence and Adverse Events
Longer antibiotic courses (more than 7 days) do not reduce the risk of early or late recurrence in men with UTI and may actually increase the risk of late recurrence and Clostridium difficile infection. Therefore, unnecessarily prolonged treatment should be avoided, especially in afebrile cases .
International Guidelines and Practice Variation
There is no international consensus on the optimal management of male UTIs. Most guidelines recommend 10–14 days of fluoroquinolones for febrile UTIs, while some Scandinavian guidelines suggest shorter courses and fluoroquinolone-sparing regimens for afebrile cases. The lack of agreement is due to limited high-quality evidence, especially for afebrile men .
Risk Factors Affecting Treatment Outcomes
Men with urinary tract catheters or prostate cancer are at higher risk for recurrence and may require closer monitoring or tailored therapy. Most men with UTI have some underlying genitourinary abnormality, and recurrent infections may require further evaluation 27.
Conclusion
For afebrile men with uncomplicated UTIs, a 7-day course of antibiotics such as nitrofurantoin, pivmecillinam, or trimethoprim-sulfamethoxazole is effective and minimizes risks. For febrile UTIs, a 14-day course of fluoroquinolones remains the standard. Overuse of antibiotics should be avoided to reduce resistance and adverse events. Individual patient factors, such as catheter use or prostate disease, should be considered when planning treatment.
Sources and full results
Most relevant research papers on this topic
Urinary tract infection in male veterans: treatment patterns and outcomes.
Longer-duration treatment for male urinary tract infections in the outpatient setting does not reduce early or late recurrence, but may increase late recurrence and Clostridium difficile infection risk.
Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men
Nitrofurantoin and pivmecillinam are suitable for treating lower urinary tract infections in men, with acceptable clinical outcomes and limited impact on intestinal microbiota.
Antimicrobial for 7 or 14 days for febrile urinary tract infection in men: a multicenter noninferiority double blind placebo-controlled, randomized clinical trial.
A 7-day ofloxacin treatment was inferior to 14-day treatment for febrile urinary tract infections in men and should not be recommended.
DOI